YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has entered a licensing agreement with Shenyang Sunshine Pharmaceutical Co., Ltd. to commercialize Clifutinib Besylate in China. The agreement involves an upfront payment of RMB 60 million, with additional milestone payments contingent on certain achievements. This strategic move aims to leverage Clifutinib’s potential in the Chinese market, while the company retains rights outside of China.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.